Claro Advisors LLC Takes Position in Incyte Co. (NASDAQ:INCY)

Claro Advisors LLC purchased a new stake in shares of Incyte Co. (NASDAQ:INCYFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,698 shares of the biopharmaceutical company’s stock, valued at approximately $255,000.

Several other hedge funds have also recently added to or reduced their stakes in INCY. Czech National Bank raised its holdings in shares of Incyte by 6.5% during the 4th quarter. Czech National Bank now owns 34,670 shares of the biopharmaceutical company’s stock valued at $2,395,000 after buying an additional 2,106 shares in the last quarter. CWA Asset Management Group LLC bought a new position in Incyte during the fourth quarter valued at approximately $1,933,000. Nordea Investment Management AB raised its stake in shares of Incyte by 9.2% during the fourth quarter. Nordea Investment Management AB now owns 13,738 shares of the biopharmaceutical company’s stock worth $945,000 after acquiring an additional 1,153 shares in the last quarter. Everence Capital Management Inc. purchased a new position in shares of Incyte during the fourth quarter worth approximately $265,000. Finally, GAMMA Investing LLC boosted its stake in shares of Incyte by 18.3% in the 4th quarter. GAMMA Investing LLC now owns 5,764 shares of the biopharmaceutical company’s stock valued at $398,000 after purchasing an additional 890 shares in the last quarter. Institutional investors own 96.97% of the company’s stock.

Wall Street Analysts Forecast Growth

INCY has been the topic of a number of analyst reports. Citigroup lifted their target price on shares of Incyte from $92.00 to $97.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. BMO Capital Markets reiterated an “underperform” rating and issued a $52.00 price objective (up previously from $48.00) on shares of Incyte in a report on Wednesday, October 30th. The Goldman Sachs Group increased their target price on Incyte from $63.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. William Blair reaffirmed an “outperform” rating on shares of Incyte in a research note on Friday, December 13th. Finally, Truist Financial reissued a “hold” rating and set a $74.00 price objective (down previously from $83.00) on shares of Incyte in a research note on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Incyte has a consensus rating of “Hold” and a consensus price target of $76.29.

Read Our Latest Analysis on Incyte

Insider Transactions at Incyte

In related news, insider Thomas Tray sold 650 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $69.31, for a total transaction of $45,051.50. Following the sale, the insider now owns 23,312 shares of the company’s stock, valued at $1,615,754.72. The trade was a 2.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Vijay K. Iyengar sold 6,043 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $75.38, for a total transaction of $455,521.34. Following the transaction, the executive vice president now directly owns 30,658 shares of the company’s stock, valued at $2,311,000.04. This represents a 16.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,023 shares of company stock valued at $839,711 in the last three months. 17.60% of the stock is currently owned by company insiders.

Incyte Stock Performance

Incyte stock opened at $72.46 on Thursday. Incyte Co. has a fifty-two week low of $50.35 and a fifty-two week high of $83.95. The stock has a market cap of $13.96 billion, a price-to-earnings ratio of 517.61, a PEG ratio of 7.90 and a beta of 0.71. The stock’s 50 day simple moving average is $72.95 and its two-hundred day simple moving average is $67.78. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.82 and a current ratio of 1.87.

Incyte (NASDAQ:INCYGet Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.12). The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.08 billion. Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. The company’s revenue for the quarter was up 23.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.91 earnings per share. As a group, analysts expect that Incyte Co. will post 0.4 earnings per share for the current fiscal year.

About Incyte

(Free Report)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

Read More

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCYFree Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.